Disruption of the blood-brain barrier after generalized tonic-clonic seizures correlates with cerebrospinal fluid MMP-9 levels

Journal of Neuroinflammation

Volumn 10, Issue , 2013, Pages

  Li, Ya Jun ^a   Wang, Zheng Hai ^b   Zhang, Bei ^a   Zhe, Xiao ^a   Wang, Ming Jue ^a   Shi, Shao Ting ^a   Bai, Jing ^a   Lin, Tao ^a   Guo, Chang Jiang ^a   Zhang, Shi Jun ^a   Kong, Xiang Li ^a   Zuo, Xing ^a   Zhao, Hang ^a  

^a XI'AN MEDICAL UNIVERSITY   (China)

^b NINGXIA MEDICAL UNIVERSITY   (China)

Author keywords

BBB; Cerebrospinal fluid; Leukocytes; Metalloproteinase 9; Seizure

Indexed keywords

GELATINASE B; SERUM ALBUMIN;

ADULT; AGED; ARTICLE; BLOOD BRAIN BARRIER; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENERALIZED TONIC CLONIC SEIZURE; HUMAN; LUMBAR PUNCTURE; MALE; PROTEIN CEREBROSPINAL FLUID LEVEL; RECURRENT DISEASE; TONIC CLONIC SEIZURE; ZYMOGRAPHY;

EID: 84879820014     PISSN: None     EISSN: 17422094     Source Type: Journal    
DOI: 10.1186/1742-2094-10-80     Document Type: Article

References (60)

1. Abbott NJ, Ronnback L, Hansson E. Astrocyte-endothelial interactions at the blood-brain barrier. Nat Rev Neurosci 2006, 7:41-53. 10.1038/nrn1824, 16371949.
2. Hawkins BT, Davis TP. The blood-brain barrier/neurovascular unit in health and disease. Pharmacol Rev 2005, 57:173-185. 10.1124/pr.57.2.4, 15914466.
3. Tomkins O, Shelef I, Kaizerman I, Eliushin A, Afawi Z, Misk A, Gidon M, Cohen A, Zumsteg D, Friedman A. Blood-brain barrier disruption in post-traumatic epilepsy. J Neurol Neurosurg Psychiatry 2008, 79:774-777. 10.1136/jnnp.2007.126425, 17991703.
4. van Vliet EA, da Costa AS, Redeker S, van Schaik R, Aronica E, Gorter JA. Blood-brain barrier leakage may lead to progression of temporal lobe epilepsy. Brain 2007, 130:521-534. 10.1093/brain/awl318, 17124188.
5. Korn A, Golan H, Melamed I, Pascual-Marqui R, Friedman A. Focal cortical dysfunction and blood-brain barrier disruption in patients with postconcussion syndrome. J Clin Neurophysiol 2005, 22:1-9. 10.1097/01.WNP.0000150973.24324.A7, 15689708.
6. Strbian D, Durukan A, Pitkonen M, Marinkovic I, Tatlisumak E, Pedrono E, Abo-Ramadan U, Tatlisumak T. The blood-brain barrier is continuously open for several weeks following transient focal cerebral ischemia. Neuroscience 2008, 153:175-181. 10.1016/j.neuroscience.2008.02.012, 18367342.
7. Correale J, Rabinowicz AL, Heck CN, Smith TD, Loskota WJ, DeGiorgio CM. Status epilepticus increases CSF levels of neuron-specific enolase and alters the blood-brain barrier. Neurology 1998, 50:1388-1391. 10.1212/WNL.50.5.1388, 9595992.
8. Friedman A. Blood-brain barrier dysfunction, status epilepticus, seizures, and epilepsy: a puzzle of a chicken and egg?. Epilepsia 2011, 52(Suppl 8):19-20. 3234990, 21967353.
9. Sahin D, Ilbay G, Ates N. Changes in the blood-brain barrier permeability and in the brain tissue trace element concentrations after single and repeated pentylenetetrazole-induced seizures in rats. Pharmacol Res 2003, 48:69-73.
10. Marchi N, Angelov L, Masaryk T, Fazio V, Granata T, Hernandez N, Hallene K, Diglaw T, Franic L, Najm I, Janigro D. Seizure-promoting effect of blood-brain barrier disruption. Epilepsia 2007, 48:732-742. 10.1111/j.1528-1167.2007.00988.x, 17319915.
11. Marchi N, Tierney W, Alexopoulos AV, Puvenna V, Granata T, Janigro D. The etiological role of blood-brain barrier dysfunction in seizure disorders. Cardiovasc Psychiatry Neurol 2011, 2011:482415. 3085334, 21541221.
12. Barr TL, Latour LL, Lee KY, Schaewe TJ, Luby M, Chang GS, El-Zammar Z, Alam S, Hallenbeck JM, Kidwell CS, Warach S. Blood-brain barrier disruption in humans is independently associated with increased matrix metalloproteinase-9. Stroke 2010, 41:e123-e128. 10.1161/STROKEAHA.109.570515, 2827673, 20035078.
13. Aoki T, Sumii T, Mori T, Wang X, Lo EH. Blood-brain barrier disruption and matrix metalloproteinase-9 expression during reperfusion injury: mechanical versus embolic focal ischemia in spontaneously hypertensive rats. Stroke 2002, 33:2711-2717. 10.1161/01.STR.0000033932.34467.97, 12411666.
14. Jin R, Yang G, Li G. Molecular insights and therapeutic targets for blood-brain barrier disruption in ischemic stroke: critical role of matrix metalloproteinases and tissue-type plasminogen activator. Neurobiol Dis 2010, 38:376-385. 10.1016/j.nbd.2010.03.008, 2862862, 20302940.
15. Gidday JM, Gasche YG, Copin JC, Shah AR, Perez RS, Shapiro SD, Chan PH, Park TS. Leukocyte-derived matrix metalloproteinase-9 mediates blood-brain barrier breakdown and is proinflammatory after transient focal cerebral ischemia. Am J Physiol Heart Circ Physiol 2005, 289:H558-H568. 10.1152/ajpheart.01275.2004, 15764676.
16. Tsai HC, Chung LY, Chen ER, Liu YC, Lee SS, Chen YS, Sy CL, Wann SR, Yen CM. Association of matrix metalloproteinase-9 and tissue inhibitors of metalloproteinase-4 in cerebrospinal fluid with blood-brain barrier dysfunction in patients with eosinophilic meningitis caused by Angiostrongylus cantonensis. Am J Trop Med Hyg 2008, 78:20-27.
17. Fernandez-Lopez D, Faustino J, Daneman R, Zhou L, Lee SY, Derugin N, Wendland MF, Vexler ZS. Blood-brain barrier permeability is increased after acute adult stroke but not neonatal stroke in the rat. J Neurosci 2012, 32:9588-9600. 10.1523/JNEUROSCI.5977-11.2012, 3539825, 22787045.
18. Berg AT, Scheffer IE. New concepts in classification of the epilepsies: entering the 21st century. Epilepsia 2011, 52:1058-1062. 10.1111/j.1528-1167.2011.03101.x, 21635233.
19. Tibbling G, Link H, Ohman S. Principles of albumin and IgG analyses in neurological disorders. I. Establishment of reference values. Scand J Clin Lab Invest 1977, 37:385-390. 10.3109/00365517709091496, 337459.
20. Ganrot K, Laurell CB. Measurement of IgG and albumin content of cerebrospinal fluid, and its interpretation. Clin Chem 1974, 20:571-573.
21. Chalbot S, Zetterberg H, Blennow K, Fladby T, Andreasen N, Grundke-Iqbal I, Iqbal K. Blood-cerebrospinal fluid barrier permeability in Alzheimer's disease. J Alzheimers Dis 2011, 25:505-515. 3139450, 21471645.
22. Sindic CJ, Van Antwerpen MP, Goffette S. The intrathecal humoral immune response: laboratory analysis and clinical relevance. Clin Chem Lab Med 2001, 39:333-340.
23. Reiber H, Padilla-Docal B, Jensenius JC, Dorta-Contreras AJ. Mannan-binding lectin in cerebrospinal fluid: a leptomeningeal protein. Fluids Barriers CNS 2012, 9:17. 10.1186/2045-8118-9-17, 3487976, 22889364.
24. Raabe A, Schmitz AK, Pernhorst K, Grote A, von der Brelie C, Urbach H, Friedman A, Becker AJ, Elger CE, Niehusmann P. Cliniconeuropathologic correlations show astroglial albumin storage as a common factor in epileptogenic vascular lesions. Epilepsia 2012, 53:539-548. 10.1111/j.1528-1167.2012.03405.x, 3669690, 22372630.
25. Marchi N, Teng Q, Ghosh C, Fan Q, Nguyen MT, Desai NK, Bawa H, Rasmussen P, Masaryk TK, Janigro D. Blood-brain barrier damage, but not parenchymal white blood cells, is a hallmark of seizure activity. Brain Res 2010, 1353:176-186. 2933328, 20599815.
26. Cornford EM. Epilepsy and the blood-brain barrier: endothelial cell responses to seizures. Adv Neurol 1999, 79:845-862.
27. Heinemann U, Kaufer D, Friedman A. Blood-brain barrier dysfunction, TGFbeta signaling, and astrocyte dysfunction in epilepsy. Glia 2012, 60:1251-1257. 10.1002/glia.22311, 3615248, 22378298.
28. Grossetete M, Phelps J, Arko L, Yonas H, Rosenberg GA. Elevation of matrix metalloproteinases 3 and 9 in cerebrospinal fluid and blood in patients with severe traumatic brain injury. Neurosurgery 2009, 65:702-708. 10.1227/01.NEU.0000351768.11363.48, 2764327, 19834375.
29. Dong X, Song YN, Liu WG, Guo XL. Mmp-9, a potential target for cerebral ischemic treatment. Curr Neuropharmacol 2009, 7:269-275. 10.2174/157015909790031157, 2811860, 20514206.
30. Michaluk P, Kaczmarek L. Matrix metalloproteinase-9 in glutamate-dependent adult brain function and dysfunction. Cell Death Differ 2007, 14:1255-1258. 10.1038/sj.cdd.4402141, 17431423.
31. Szklarczyk A, Lapinska J, Rylski M, McKay RD, Kaczmarek L. Matrix metalloproteinase-9 undergoes expression and activation during dendritic remodeling in adult hippocampus. J Neurosci 2002, 22:920-930.
32. Michaluk P, Wawrzyniak M, Alot P, Szczot M, Wyrembek P, Mercik K, Medvedev N, Wilczek E, De Roo M, Zuschratter W, et al. Influence of matrix metalloproteinase MMP-9 on dendritic spine morphology. J Cell Sci 2011, 124:3369-3380. 10.1242/jcs.090852, 21896646.
33. Wang XB, Bozdagi O, Nikitczuk JS, Zhai ZW, Zhou Q, Huntley GW. Extracellular proteolysis by matrix metalloproteinase-9 drives dendritic spine enlargement and long-term potentiation coordinately. Proc Natl Acad Sci U S A 2008, 105:19520-19525. 10.1073/pnas.0807248105, 2614793, 19047646.
34. Hoehna Y, Uckermann O, Luksch H, Stefovska V, Marzahn J, Theil M, Gorkiewicz T, Gawlak M, Wilczynski GM, Kaczmarek L, Ikonomidou C. Matrix metalloproteinase 9 regulates cell death following pilocarpine-induced seizures in the developing brain. Neurobiol Dis 2012, 48:339-347. 10.1016/j.nbd.2012.06.023, 22782080.
35. Nagy V, Bozdagi O, Matynia A, Balcerzyk M, Okulski P, Dzwonek J, Costa RM, Silva AJ, Kaczmarek L, Huntley GW. Matrix metalloproteinase-9 is required for hippocampal late-phase long-term potentiation and memory. J Neurosci 2006, 26:1923-1934. 10.1523/JNEUROSCI.4359-05.2006, 16481424.
36. Konopka A, Grajkowska W, Ziemianska K, Roszkowski M, Daszkiewicz P, Rysz A, Marchel A, Koperski L, Wilczynski GM, Dzwonek J. Matrix metalloproteinase-9 (MMP-9) in human intractable epilepsy caused by focal cortical dysplasia. Epilepsy Res 2013, 104:45-58. 10.1016/j.eplepsyres.2012.09.018, 23182966.
37. Li S, Yu S, Zhang C, Shu H, Liu S, An N, Yang M, Yin Q, Yang H. Increased expression of matrix metalloproteinase 9 in cortical lesions from patients with focal cortical dysplasia type IIb and tuberous sclerosis complex. Brain Res 2012, 1453:46-55.
38. Mizoguchi H, Nakade J, Tachibana M, Ibi D, Someya E, Koike H, Kamei H, Nabeshima T, Itohara S, Takuma K, et al. Matrix metalloproteinase-9 contributes to kindled seizure development in pentylenetetrazole-treated mice by converting pro-BDNF to mature BDNF in the hippocampus. J Neurosci 2011, 31:12963-12971. 10.1523/JNEUROSCI.3118-11.2011, 21900575.
39. Wilczynski GM, Konopacki FA, Wilczek E, Lasiecka Z, Gorlewicz A, Michaluk P, Wawrzyniak M, Malinowska M, Okulski P, Kolodziej LR, et al. Important role of matrix metalloproteinase 9 in epileptogenesis. J Cell Biol 2008, 180:1021-1035. 10.1083/jcb.200708213, 2265409, 18332222.
40. Lahteinen S, Pitkanen A, Koponen E, Saarelainen T, Castren E. Exacerbated status epilepticus and acute cell loss, but no changes in epileptogenesis, in mice with increased brain-derived neurotrophic factor signaling. Neuroscience 2003, 122:1081-1092. 10.1016/j.neuroscience.2003.08.037, 14643774.
41. Scharfman HE, Goodman JH, Sollas AL, Croll SD. Spontaneous limbic seizures after intrahippocampal infusion of brain-derived neurotrophic factor. Exp Neurol 2002, 174:201-214. 10.1006/exnr.2002.7869, 11922662.
42. Croll SD, Suri C, Compton DL, Simmons MV, Yancopoulos GD, Lindsay RM, Wiegand SJ, Rudge JS, Scharfman HE. Brain-derived neurotrophic factor transgenic mice exhibit passive avoidance deficits, increased seizure severity and in vitro hyperexcitability in the hippocampus and entorhinal cortex. Neuroscience 1999, 93:1491-1506. 10.1016/S0306-4522(99)00296-1, 2504500, 10501474.
43. Xu B, Michalski B, Racine RJ, Fahnestock M. The effects of brain-derived neurotrophic factor (BDNF) administration on kindling induction, Trk expression and seizure-related morphological changes. Neuroscience 2004, 126:521-531. 10.1016/j.neuroscience.2004.03.044, 15183502.
44. Kim GW, Kim HJ, Cho KJ, Kim HW, Cho YJ, Lee BI. The role of MMP-9 in integrin-mediated hippocampal cell death after pilocarpine-induced status epilepticus. Neurobiol Dis 2009, 36:169-180. 10.1016/j.nbd.2009.07.008, 19631748.
45. Takacs E, Nyilas R, Szepesi Z, Baracskay P, Karlsen B, Rosvold T, Bjorkum AA, Czurko A, Kovacs Z, Kekesi AK, Juhasz G. Matrix metalloproteinase-9 activity increased by two different types of epileptic seizures that do not induce neuronal death: a possible role in homeostatic synaptic plasticity. Neurochem Int 2010, 56:799-809. 10.1016/j.neuint.2010.03.003, 20303372.
46. Paul R, Lorenzl S, Koedel U, Sporer B, Vogel U, Frosch M, Pfister HW. Matrix metalloproteinases contribute to the blood-brain barrier disruption during bacterial meningitis. Ann Neurol 1998, 44:592-600. 10.1002/ana.410440404, 9778257.
47. Matsuura E, Umehara F, Hashiguchi T, Fujimoto N, Okada Y, Osame M. Marked increase of matrix metalloproteinase 9 in cerebrospinal fluid of patients with fungal or tuberculous meningoencephalitis. J Neurol Sci 2000, 173:45-52. 10.1016/S0022-510X(99)00303-2, 10675579.
48. Brown HC, Chau TT, Mai NT, Day NP, Sinh DX, White NJ, Hien TT, Farrar J, Turner GD. Blood-brain barrier function in cerebral malaria and CNS infections in Vietnam. Neurology 2000, 55:104-111. 10.1212/WNL.55.1.104, 10891914.
49. Guo M, Cox B, Mahale S, Davis W, Carranza A, Hayes K, Sprague S, Jimenez D, Ding Y. Pre-ischemic exercise reduces matrix metalloproteinase-9 expression and ameliorates blood-brain barrier dysfunction in stroke. Neuroscience 2008, 151:340-351. 10.1016/j.neuroscience.2007.10.006, 18160227.
50. Wang Z, Meng CJ, Shen XM, Shu Z, Ma C, Zhu GQ, Liu HX, He WC, Sun XB, Huo L, et al. Potential contribution of hypoxia-inducible factor-1alpha, aquaporin-4, and matrix metalloproteinase-9 to blood-brain barrier disruption and brain edema after experimental subarachnoid hemorrhage. J Mol Neurosci 2012, 48:273-280. 10.1007/s12031-012-9769-6, 22528459.
51. Fainardi E, Castellazzi M, Bellini T, Manfrinato MC, Baldi E, Casetta I, Paolino E, Granieri E, Dallocchio F. Cerebrospinal fluid and serum levels and intrathecal production of active matrix metalloproteinase-9 (MMP-9) as markers of disease activity in patients with multiple sclerosis. Mult Scler 2006, 12:294-301. 10.1191/135248506ms1274oa, 16764342.
52. Higashida T, Kreipke CW, Rafols JA, Peng C, Schafer S, Schafer P, Ding JY, Dornbos D, Li X, Guthikonda M, et al. The role of hypoxia-inducible factor-1alpha, aquaporin-4, and matrix metalloproteinase-9 in blood-brain barrier disruption and brain edema after traumatic brain injury. J Neurosurg 2011, 114:92-101. 10.3171/2010.6.JNS10207, 20617879.
53. Yin P, Yang L, Zhou HY, Sun RP. Matrix metalloproteinase-9 may be a potential therapeutic target in epilepsy. Med Hypotheses 2011, 76:184-186. 10.1016/j.mehy.2010.09.013, 20888701.
54. Ralay Ranaivo H, Hodge JN, Choi N, Wainwright MS. Albumin induces upregulation of matrix metalloproteinase-9 in astrocytes via MAPK and reactive oxygen species-dependent pathways. J Neuroinflammation 2012, 9:68. 10.1186/1742-2094-9-68, 3419618, 22507553.
55. Silverberg J, Ginsburg D, Orman R, Amassian V, Durkin HG, Stewart M. Lymphocyte infiltration of neocortex and hippocampus after a single brief seizure in mice. Brain Behav Immun 2010, 24:263-272. 10.1016/j.bbi.2009.10.006, 19822204.
56. Zattoni M, Mura ML, Deprez F, Schwendener RA, Engelhardt B, Frei K, Fritschy JM. Brain infiltration of leukocytes contributes to the pathophysiology of temporal lobe epilepsy. J Neurosci 2011, 31:4037-4050. 10.1523/JNEUROSCI.6210-10.2011, 21411646.
57. Fabene PF, Navarro Mora G, Martinello M, Rossi B, Merigo F, Ottoboni L, Bach S, Angiari S, Benati D, Chakir A, et al. A role for leukocyte-endothelial adhesion mechanisms in epilepsy. Nat Med 2008, 14:1377-1383. 10.1038/nm.1878, 2710311, 19029985.
58. Fabene PF, Laudanna C, Constantin G. Leukocyte trafficking mechanisms in epilepsy. Mol Immunol 2013, 55:100-104. 10.1016/j.molimm.2012.12.009, 23351392.
59. Takahashi Y, Imai K, Ikeda H, Kubota Y, Yamazaki E, Susa F. Open study of pranlukast add-on therapy in intractable partial epilepsy. Brain Dev 2013, 35:236-244. 10.1016/j.braindev.2012.04.001, 22571867.
60. Wang Z, Leng Y, Tsai LK, Leeds P, Chuang DM. Valproic acid attenuates blood-brain barrier disruption in a rat model of transient focal cerebral ischemia: the roles of HDAC and MMP-9 inhibition. J Cereb Blood Flow Metab 2011, 31:52-57. 10.1038/jcbfm.2010.195, 3049473, 20978517.